Dental Care Clinics in Erin, TN Accepting Medicare
2 Dental Care Clinics found. Showing 1 - 2
 Erin Family Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 4889 E Main St, Erin, TN 37061 Phone: 931-289-2200 |
Hilcrest Dental Clinic Inc. Dentist Medicare: Not Enrolled in Medicare Practice Location: 4889 E Main St, Erin, TN 37061 Phone: 931-289-3122 Fax: 931-289-5832 |
News Archive
Use of gloves, gowns by health care workers for ICU patient contact does not reduce MRSA infection
The wearing of gloves and gowns by health care workers for all intensive care unit (ICU) patient contact did not reduce the rate of acquisition of a combination of the bacteria methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), although there was a lower risk of MRSA acquisition alone, according to a study published online by JAMA.
GfK survey: 3 in 10 people are not confident of leading quality life during retirement
Internationally, close to three in ten (28 percent) lack confidence that they will be able to afford the life they want during retirement, including one in ten (11 percent) who have no confidence in this at all. On the other hand, 42 percent believe they will have enough money for the life they want, including 18 percent who are completely confident.
UCR researchers gauge social responsibility in reducing COVID-19 spread
Uncertainty and anxiety generated by the COVID-19 pandemic motivated social psychologist Evelyn Vázquez at the University of California, Riverside, to collaborate with UCR Healthy Campus on a study to identify safety measures and public health messaging that reduce the spread of the coronavirus within campus communities.
Par Pharmaceutical enters definitive agreement to acquire Anchen
Par Pharmaceutical Companies, Inc. announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash.
OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.
› Verified 5 days ago